Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.

Lenze EJ, Mantella RC, Shi P, Goate AM, Nowotny P, Butters MA, Andreescu C, Thompson PA, Rollman BL.

Am J Geriatr Psychiatry. 2011 May;19(5):482-90. doi: 10.1097/JGP.0b013e3181ec806c.

2.

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.

Lenze EJ, Goate AM, Nowotny P, Dixon D, Shi P, Bies RR, Lotrich FK, Rollman BL, Shear MK, Thompson PA, Andreescu C, Pollock BG.

J Clin Psychopharmacol. 2010 Dec;30(6):672-7.

3.

Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.

Lenze EJ, Dixon D, Mantella RC, Dore PM, Andreescu C, Reynolds CF 3rd, Newcomer JW, Butters MA.

Int J Geriatr Psychiatry. 2012 May;27(5):454-62. doi: 10.1002/gps.2732. Epub 2011 Jun 17.

4.

Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial.

Rosnick CB, Wetherell JL, White KS, Andreescu C, Dixon D, Lenze EJ.

J Consult Clin Psychol. 2016 Apr;84(4):345-52. doi: 10.1037/a0040113. Epub 2016 Feb 15.

5.

The effect of escitalopram versus placebo on perceived stress and salivary cortisol in healthy first-degree relatives of patients with depression-A randomised trial.

Knorr U, Vinberg M, Gether U, Winkel P, Gluud C, Wetterslev J, Kessing LV.

Psychiatry Res. 2012 Dec 30;200(2-3):354-60. doi: 10.1016/j.psychres.2012.05.015. Epub 2012 Jun 14.

PMID:
22703642
6.

Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure.

Oberlander TF, Grunau R, Mayes L, Riggs W, Rurak D, Papsdorf M, Misri S, Weinberg J.

Early Hum Dev. 2008 Oct;84(10):689-97. doi: 10.1016/j.earlhumdev.2008.06.008. Epub 2008 Jul 18.

7.

Contrasting effects of citalopram and reboxetine on waking salivary cortisol.

Harmer CJ, Bhagwagar Z, Shelley N, Cowen PJ.

Psychopharmacology (Berl). 2003 Apr;167(1):112-4. Epub 2003 Feb 26.

PMID:
12605289
8.

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.

Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, Andreescu C, Butters MA, Reynolds CF 3rd.

JAMA. 2009 Jan 21;301(3):295-303. doi: 10.1001/jama.2008.977.

9.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
10.

Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive Disorder.

Ruhé HG, Khoenkhoen SJ, Ottenhof KW, Koeter MW, Mocking RJ, Schene AH.

Psychoneuroendocrinology. 2015 Feb;52:261-71. doi: 10.1016/j.psyneuen.2014.10.024. Epub 2014 Nov 26.

11.

Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function.

Pawluski JL, Brain UM, Underhill CM, Hammond GL, Oberlander TF.

Psychoneuroendocrinology. 2012 Jul;37(7):1019-28. doi: 10.1016/j.psyneuen.2011.11.011. Epub 2011 Dec 15.

PMID:
22177580
12.

Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.

Garfield LD, Dixon D, Nowotny P, Lotrich FE, Pollock BG, Kristjansson SD, Doré PM, Lenze EJ.

Am J Geriatr Psychiatry. 2014 Oct;22(10):971-9. doi: 10.1016/j.jagp.2013.07.003. Epub 2013 Sep 8.

13.

Treatment of abdominally obese men with a serotonin reuptake inhibitor: a pilot study.

Ljung T, Ahlberg AC, Holm G, Friberg P, Andersson B, Eriksson E, Björntorp P.

J Intern Med. 2001 Sep;250(3):219-24.

15.

Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.

Nothdurfter C, Schmotz C, Sarubin N, Baghai TC, Laenger A, Lieb M, Bondy B, Rupprecht R, Schüle C.

J Psychiatr Res. 2014 May;52:15-20. doi: 10.1016/j.jpsychires.2014.01.013. Epub 2014 Jan 31.

PMID:
24513501
16.

Salivary cortisol is associated with diagnosis and severity of late-life generalized anxiety disorder.

Mantella RC, Butters MA, Amico JA, Mazumdar S, Rollman BL, Begley AE, Reynolds CF, Lenze EJ.

Psychoneuroendocrinology. 2008 Jul;33(6):773-81. doi: 10.1016/j.psyneuen.2008.03.002. Epub 2008 Apr 14.

17.

Salivary cortisol levels and the 2-year course of depressive and anxiety disorders.

Vreeburg SA, Hoogendijk WJ, DeRijk RH, van Dyck R, Smit JH, Zitman FG, Penninx BW.

Psychoneuroendocrinology. 2013 Sep;38(9):1494-502. doi: 10.1016/j.psyneuen.2012.12.017. Epub 2013 Jan 11.

18.

Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats.

Jensen JB, Jessop DS, Harbuz MS, Mørk A, Sánchez C, Mikkelsen JD.

J Neuroendocrinol. 1999 Jun;11(6):465-71.

PMID:
10336728
19.

Effect of escitalopram versus placebo on GRα messenger RNA expression in peripheral blood cells of healthy individuals with a family history of depression - a secondary outcome analysis from the randomized AGENDA trial.

Knorr U, Koefoed P, Gluud C, Wetterslev J, Winkel P, Gether U, Vinberg M, Kessing LV.

Nord J Psychiatry. 2016;70(4):297-302. doi: 10.3109/08039488.2015.1109138. Epub 2016 Jan 11.

PMID:
26752119
20.

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.

Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.

Depress Anxiety. 2010 May;27(5):417-25. doi: 10.1002/da.20695.

PMID:
20455246

Supplemental Content

Support Center